NAOV NanoVibronix, Inc. Stock Quote

NAOV [NASD]

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	0.10%	Shs Outstand	19.31M	Perf Week	0.00%
Market Cap	24.69M	Forward P/E	-	EPS next Y	-	Insider Trans	91.58%	Shs Float	13.68M	Perf Month	5.36%
Income	-4.50M	PEG	-	EPS next Q	-	Inst Own	12.10%	Short Float	1.04%	Perf Quarter	55.26%
Sales	0.60M	P/S	41.14	EPS this Y	-26.10%	Inst Trans	59.27%	Short Ratio	0.04	Perf Half Y	68.60%
Book/sh	0.35	P/B	3.37	EPS next Y	-	ROA	-218.30%	Target Price	-	Perf Year	-57.86%
Cash/sh	0.15	P/C	7.71	EPS next 5Y	-	ROE	-418.50%	52W Range	0.54 - 3.50	Perf YTD	54.43%
Dividend	-	P/FCF	-	EPS past 5Y	39.60%	ROI	-417.10%	52W High	-67.12%	Beta	-0.15
Dividend %	-	Quick Ratio	10.40	Sales past 5Y	21.20%	Gross Margin	26.10%	52W Low	115.06%	ATR	0.18
Employees	10	Current Ratio	10.70	Sales Q/Q	100.00%	Oper. Margin	-	RSI (14)	44.30	Volatility	14.79% 12.35%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	46.40%	Profit Margin	-	Rel Volume	0.20	Prev Close	1.18
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	3.90M	Price	1.15
Recom	2.00	SMA20	-13.34%	SMA50	1.51%	SMA200	-5.16%	Volume	45,233	Change	-2.47%

Mar-02-21 08:30AM	NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market Business Wire
Feb-10-21 08:00AM	NanoVibronix Reports Schedule Published by NICE for Review of UroShield® Device Business Wire
Feb-03-21 08:00AM	NanoVibronix Regains Nasdaq Compliance Business Wire +7.03%
Jan-22-21 11:12AM	NAOV Stock: 7 Things to Know About Medical Device Company NanoVibronix InvestorPlace
Jan-19-21 08:00AM	NanoVibronix Issues Letter to Shareholders Business Wire
Dec-11-20 08:00AM	NanoVibronix Amends and Expands Distribution Agreement for Its PainShield® and PainShield Plus® Business Wire +6.28%
Dec-08-20 08:00AM	NanoVibronix Announces UroShield and PainShield Meet New Zealand Medicines and Medical Devices Safety Authority Regulatory Requirements Business Wire +9.00%
Dec-07-20 05:10PM	NanoVibronix Announces Closing of $6.0 Million Private Placement Priced At-the-Market Business Wire -8.26%
Dec-02-20 01:01PM	NanoVibronix Announces $6.0 Million Private Placement Business Wire +55.17%
07:54AM	Independent Study Finds Significant Benefits Provided by NanoVibronixs UroShield® Device Business Wire
Nov-16-20 06:12PM	NanoVibronix Reports Third Quarter 2020 Financial Results, Provides Business Update Business Wire
Oct-16-20 08:30AM	NanoVibronix Expands Offerings with Introduction of PainShield Plus® Business Wire
Oct-08-20 09:00AM	NanoVibronix Receives Positive Nasdaq Listing Determination Business Wire
Sep-29-20 08:49AM	NanoVibronix Files U.S. Patent Application for PainShield® for Delivery of Cannabinoids for Alleviation of Chronic and Acute Pain PR Newswire
Sep-22-20 08:36PM	NanoVibronix Increases Previously Announced Bought Deal to $1.8 Million PR Newswire +103.46%
06:11PM	NanoVibronix Announces $1.5 Million Bought Deal Offering PR Newswire
10:37AM	Why NanoVibronix's Stock Is Trading Higher Today Benzinga
08:00AM	NanoVibronix UroShield® Receives U.S. Food and Drug Administration Authorization for Entry into the U.S. PR Newswire
Aug-27-20 03:42PM	NanoVibronix Announces Closing of $3.4 Million Bought Deal Offering and Partial Exercise of Underwriter's Option to Purchase Additional Shares PR Newswire
Aug-24-20 10:58PM	NanoVibronix Increases Previously Announced Bought Deal to $3.25 Million PR Newswire -10.52%
05:23PM	NanoVibronix Announces $2.5 Million Bought Deal Offering PR Newswire
Aug-13-20 08:30AM	NanoVibronix Announces First Shipments of new UroShield Devices PR Newswire -13.51%
Jul-07-20 08:00AM	NanoVibronix Signs Two Year, Exclusive Distribution Agreement for PainShield PR Newswire +6.76%
Jun-16-20 08:00AM	NanoVibronix Fulfills its First Private Label Partnership with Medisana and Receives Award for PainShield PT 100 Quality PR Newswire +9.35%
Jun-01-20 08:00AM	NanoVibronix Expands License Agreement for UroShield® and PainShield with Existing Distributor to Include Canada and Turkey PR Newswire
Apr-02-20 11:06AM	SANUWAVE Health Announces Exclusive Licensing of NanoVibronix, Inc. Surface Acoustic Wave Ultrasound Technology GlobeNewswire
08:00AM	NanoVibronix Announces License Agreement for WoundShield Product PR Newswire
Apr-01-20 08:00AM	NanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield GlobeNewswire +8.84%

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FASHEK CHRISTOPHER M	Director	Sep 29	Buy	0.79	10,000	7,887	10,000	Oct 09 04:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience